RT Book, Section A1 Jameson, J. Larry A1 Longo, Dan L. A2 Longo, Dan L. SR Print(0) ID 1128358341 T1 PARANEOPLASTIC SYNDROMES: ENDOCRINOLOGIC AND HEMATOLOGIC T2 Harrison's Hematology and Oncology, 2e YR 2013 FD 2013 PB McGraw-Hill Education PP New York, NY SN 9780071814904 LK hemonc.mhmedical.com/content.aspx?aid=1128358341 RD 2024/03/28 AB In addition to local tissue invasion and metastasis, neoplastic cells can produce a variety of products that can stimulate hormonal, hematologic, dermatologic, and neurologic responses. Paraneoplastic syndromes is the term used to refer to the disorders that accompany benign or malignant tumors but are not directly related to mass effects or invasion. Tumors of neuroendocrine origin, such as small cell lung carcinoma (SCLC) and carcinoids, produce a wide array of peptide hormones and are common causes of paraneoplastic syndromes. However, almost every type of tumor has the potential to produce hormones or cytokines or to induce immunologic responses. Careful studies of the prevalence of paraneoplastic syndromes indicate that they are more common than is generally appreciated. The signs, symptoms, and metabolic alterations associated with paraneoplastic disorders may be overlooked in the context of a malignancy and its treatment. Consequently, atypical clinical manifestations in a patient with cancer should prompt consideration of a paraneoplastic syndrome. The most common endocrinologic and hematologic syndromes associated with underlying neoplasia will be discussed here.